Immunoprecise Antibodies Ltd
XTSX:IPA

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
XTSX:IPA
Watchlist
Price: 6.5 CAD 0.78% Market Closed
Market Cap: 161.4m CAD

Immunoprecise Antibodies Ltd
Other Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Immunoprecise Antibodies Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Immunoprecise Antibodies Ltd
XTSX:IPA
Other Current Assets
CA$1.8m
CAGR 3-Years
74%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abcellera Biologics Inc
NASDAQ:ABCL
Other Current Assets
$33.6m
CAGR 3-Years
4%
CAGR 5-Years
117%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Other Current Assets
CA$4.7k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Other Current Assets
CA$211.8k
CAGR 3-Years
86%
CAGR 5-Years
54%
CAGR 10-Years
36%
No Stocks Found

Immunoprecise Antibodies Ltd
Glance View

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.

IPA Intrinsic Value
Not Available

See Also

What is Immunoprecise Antibodies Ltd's Other Current Assets?
Other Current Assets
1.8m CAD

Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Other Current Assets amounts to 1.8m CAD.

What is Immunoprecise Antibodies Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
74%

Over the last year, the Other Current Assets growth was 236%. The average annual Other Current Assets growth rates for Immunoprecise Antibodies Ltd have been 74% over the past three years .

Back to Top